BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies

  GRO Biosciences Inc. presented successful proof of concept results in two pre-clinical programs representing potential breakthroughs in autoimmune disease and immunogenicity at this week’s Discovery On Target conference.

  September 27, 2023

   · 

  3 min read
• Policy

  BrainStorm Cell Therapeutics Stock Trading Halted Today

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that Nasdaq has halted trading of the Company’s common stock.

  September 27, 2023

   · 

  7 min read
• Business

  Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer

  Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

  September 27, 2023

   · 

  7 min read
• Drug Development

  Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes

  Kallyope, Inc. today announced the initiation of their Phase 2 trial evaluating K-757 and K-833.

  September 27, 2023

   · 

  4 min read
• Business

  Biomind Labs Provides Corporate Update

  Biomind Labs Inc. provides a corporate update outlining its research and development, intellectual property and clinical trials initiatives.

  September 27, 2023

   · 

  9 min read
• Drug Development

  Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

  Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

  September 27, 2023

   · 

  5 min read
• Business

  Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan

  Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.

  September 27, 2023

   · 

  4 min read
• Appili Therapeutics Presents at the 10th International Tularemia Conference

  Appili Therapeutics Inc. today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023.

  September 27, 2023

   · 

  3 min read
• Pharm Country

  Indaptus Therapeutics to Present at the LD Micro Main Event XVI

  Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI.

  September 27, 2023

   · 

  6 min read
• Pharm Country

  Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

  Vaccinex, Inc today announced that it will present data on a new ActivMAb® application on September 28th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29th.

  September 27, 2023

   · 

  7 min read